Remdesivir, known by the brand name Veklury, is an intravenous antiviral medication developed by Gilead Sciences to treat COVID-19 in hospitalized patients and certain high-risk individuals. Authorized for emergency use in May 2020 and later receiving full FDA approval in October 2020, it works by inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase enzyme, effectively stopping the virus from replicating within human cells.
How Remdesivir Works in the Body
At its core, remdesivir is a prodrug, meaning it must be metabolized by the body into its active form, remdesivir triphosphate (RDV-TP), to function. According to MedicineNet, once converted, this active molecule integrates itself into the growing viral RNA chain. By doing so, it terminates the synthesis process, preventing the virus from creating copies of itself. This mechanism is specifically targeted at the SARS-CoV-2 virus, the pathogen responsible for the COVID-19 pandemic.
Who Is Eligible for Treatment?
Clinical eligibility for remdesivir has evolved since its initial authorization. According to Mayo Clinic, the drug is primarily indicated for patients hospitalized with COVID-19. Additionally, Drugs.com notes that the medication is approved for use in adults and children from birth, provided they meet specific weight requirements of at least 3 pounds (1.5 kilograms). Because it is administered via intravenous infusion, treatment typically occurs in a healthcare setting where medical professionals can monitor the patient.
Safety Considerations and Side Effects
Medical providers must carefully screen patients before and during treatment. The MedicineNet report highlights that clinicians should perform liver function tests before starting therapy, as the medication can lead to an elevation of liver enzymes, known as transaminases. If a patient’s ALT levels rise significantly—specifically above 10 times the upper normal limit—physicians may consider discontinuing the drug.
Hypersensitivity is another clinical concern. Some patients experience infusion-related or anaphylactic reactions, often appearing within an hour of administration. To mitigate these risks, healthcare providers may choose to slow the infusion rate, sometimes extending it up to 120 minutes. If a clinically significant reaction occurs, the standard protocol is to stop the infusion immediately and provide appropriate medical intervention.
Key Facts About Remdesivir Administration
- Drug Class: Antiviral, specifically targeting SARS-CoV-2.
- Administration: Intravenous (IV) infusion only.
- Development: Created by the biopharmaceutical company Gilead Sciences.
- Regulatory Status: Granted Emergency Use Authorization in May 2020; received full FDA approval in October 2020.
As treatment protocols for COVID-19 continue to be refined by global health authorities, remdesivir remains a foundational tool in the clinical management of the disease. Patients should always consult with their healthcare team to determine if this antiviral therapy is appropriate based on their specific health history and the severity of their infection.